GleamWall
中文EN

PTN PALATIN TECHNOLOGIES INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 911216 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-276.9%
TTM EPS YoY-4.0%
Revenue 3-yr CAGR-61.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,354.1%
Net margin-5,261.5%
FCF margin—
EBITDA margin-5,335.2%

Returns

ROE-1,495.4%
ROA-271.7%
ROIC (approx.)—
Asset turnover0.05x

Leverage & solvency

Liabilities / assets57.1%
Debt / equity0.00x
Current ratio1.67x
Interest coverage-2,873.67x

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-36.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue$361,802-$4.05M$3.92M$116,036$8.83M$0$0—
R&D expense$3.38M$2.01M$3.52M$4.32M$2.53M$1.97M$3.76M$3.43M
SG&A expense$2.08M$2.71M$1.98M$3.12M$1.66M$2.63M$1.47M$1.68M
Operating income-$5.10M-$4.42M-$1.58M-$7.33M$4.66M-$2.27M-$4.81M-$2.61M
Interest expense$1,690$2,958$1,268$498$2,002$3,487$1,795$3,803
Net income-$5.06M-$4.36M-$1.43M-$7.26M$4.68M-$2.23M-$4.81M-$2.44M
EBITDA-$5.09M-$4.40M-$1.56M-$7.31M$4.68M-$2.22M-$4.76M-$2.54M
EPS (basic)-1.29—-0.37-2.864.81—-9.13-5.92
EPS (diluted)-1.29—-0.37-2.864.26—-9.13-5.92
Weighted avg. shares (diluted)3.92M—3.91M2.54M1.10M—526,891412,697
Balance sheet
Cash & equivalents$3.74M$7.49M$10.16M$14.48M$8.24M$9.53M$2.52M$3.42M
Receivables$361,802$300,770—$1.64M$6.89M$0——
Current assets$4.44M$8.16M$12.79M$17.47M$8.37M$2.92M$3.23M$3.67M
PP&E, net$101,112$118,064$135,016$113,485$115,057$129,444$182,437$235,741
Total assets$4.72M$8.52M$13.23M$17.93M$8.61M$3.27M$3.73M$4.31M
Current liabilities$2.66M$1.77M$2.54M$6.33M$8.22M$8.01M$10.05M$9.56M
Total liabilities$2.69M$1.84M$2.63M$6.46M$8.22M$8.04M$10.12M$10.69M
Shareholders' equity$2.03M$6.69M$10.59M$11.47M$396,399-$4.78M-$6.39M-$6.38M
Shares outstanding1.78M1.78M1.78M1.76M973,291929,59728.56M23.46M
Cash flow statement
Operating cash flow-$3.74M-$2.69M-$4.42M-$4.81M-$1.62M-$4.09M-$5.35M-$4.85M
Capital expenditure—$0$38,483——$0$0—
Free cash flow—-$2.69M-$4.46M——-$4.09M-$5.35M—
Investing cash flow—$0-$38,483——$630,000$0$2.50M
Financing cash flow-$10,001$22,500$138,878$18.02M$328,200$3.50M$4.46M$3.38M
Depreciation & amortization$16,952$16,952$16,952$14,388$14,387$52,993$53,304$71,830
Stock-based compensation$407,126$430,668$419,968$310,740$167,711$336,612$347,691$348,955

Free plan shows the latest 8 periods; Pro shows all 65 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.